Podcasts about Kluger

Die US-Notenbank FED lässt den Leitzins unverändert. Trotz des Druckes von US-Präsident Donald Trump, der eine deutliche Senkung fordert. Ein kluger Entscheid? Und was bedeutet das für die Schweizer Notenbank SNB? Weitere Themen: Seit dem Amtsantritt von US-Präsident Donald Trump stehen die Universitäten in den USA unter Druck. Forschende überlegen sich, den USA den Rücken zu kehren und an eine europäische Universität zu wechseln. Die EU will diesen Forschenden die Hand reichen. Davon profitiert auch die Schweiz. Die Asiatische Hornisse, der Laubholzbockkäfer oder die Kirschessigfliege: Viele solcher in die Schweiz eingeschleppten Insektenarten verursachen ökologische und ökonomische Schäden. In einem Labor im Jura suchen und züchten Forscherinnen und Forscher natürliche Feinde gegen die invasiven Tierchen.

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Biesler, Jörg www.deutschlandfunk.de, Kultur heute

KI kann Fehler machen. Eine Fehlerquelle ist der Kluger-Hans-Effekt: KI-Modelle kommen zwar zum richtigen Ergebnis – aber aufgrund falscher Infos. Die KI lernt also falsch – und mögliche Fehler fallen in der Testphase oft nicht auf.

Wann macht es Sinn, eine Immobilie zu verkaufen – selbst wenn sie profitabel ist?In dieser Episode sprechen wir darüber, warum Martin sich dazu entschieden hat, eine Immobilie privat vor Ablauf der 10-Jahres-Frist zu verkaufen, obwohl er dadurch Steuern auf den Gewinn zahlen muss.Martin nimmt uns mit auf seine Reise und erklärt, welche Herausforderungen mit dieser Immobilie verbunden waren, warum sie nicht mehr zu seiner Strategie passte und welche Lehren er daraus für zukünftige Investments zieht.Wir sprechen darüber:✔️ Warum sich Martins Strategie in den letzten Jahren verändert hat✔️ Welche Probleme im Objekt dazu geführt haben, dass er sich für den Verkauf entschieden hat✔️ Welche finanziellen Faktoren in die Entscheidung eingeflossen sind✔️ Warum Cashflow nicht immer das wichtigste Kriterium ist✔️ Wie Opportunitätskosten eine entscheidende Rolle spielen✔️ Ob es Sinn macht, vor Ablauf der 10 Jahre Steuern auf den Gewinn in Kauf zu nehmen✔️ Wie er die Verkaufsentscheidung in seine langfristige Strategie integriertAuch wenn viele Immobilien-Investoren die 10-Jahres-Haltefrist als feste Regel sehen, zeigt diese Folge, dass es sinnvoll sein kann, eine Immobilie frühzeitig abzugeben – wenn die Strategie es erfordert.Dieser Podcast wird unterstützt von ⁠⁠⁠Ohne-Makler.net⁠⁠⁠

Robert Kluger, Chief Development Officer at Kura Sushi, joins Matt to share the story behind Kura Sushi, a revolving sushi bar restaurant originating from Japan. He discusses how Kura Sushi leverages technology, such as revolving sushi belts and drink robots, to enhance labor efficiency and create unforgettable customer experiences. Robert, who has held leadership roles at industry giants like Panda Express, Panera Bread, and Blaze Pizza, also shares his personal expertise in scaling restaurant brands and selecting prime real estate in today's competitive market.About Robert KlugerMr. Kluger has served as Chief Development Officer of Kura Sushi USA since May 2020. Most recently, Mr. Kluger served for four years as Senior Vice President of Development and Vice President of Real Estate for Blaze Pizza, LLC, a fast casual artisan pizza brand with approximately 340 units worldwide. Blaze Pizza added over 200 franchise-operated restaurants during Mr. Kluger's tenure. Prior to Blaze Pizza, he spend 6 years at Panera Bread, the largest bakery-café concept in the U.S. also with a presence in Canada, as their Senior Development Manager. During his first 3 years at Panera Bread, Mr. Kluger rapidly grew Panera Bread's footprint in Southern California opening both company and franchise operated bakery-cafés, then in his last 3 years was charged with leading franchise development nationwide. During Mr. Kluger's tenure, Panera Bread opened approximately 800 bakery-cafes. Previously, he spent 12 years at Panda Restaurant Group and held various roles including Vice President of Real Estate. Panda Restaurant Group, parent to Panda Express, Panda Inn and Hibachi San is the largest quick service Chinese restaurant chain in the U.S. and internationally. Mr. Kluger was charged with growing Panda Express in traditional and non-traditional venues across the United States. Panda Express opened approximately 1,300 restaurants during Mr. Kluger's tenure. Mr. Kluger started his career in field operations and a corporate capital planner and financial analyst at The Vons Companies Inc., at the time the largest grocery chain in Southern California with over 300 units and $5 billion in total sales. About Kura SushiSince the opening of its first restaurant in 1977, our parent company, Kura Corporation and Kura Sushi USA have grown to over 600 locations across Japan, Taiwan, and the United States. As pioneers of the “revolving sushi” concept, the Kura family of companies have improved upon the idea and developed innovative systems that combine advanced technology, premium ingredients, and affordable prices to create a unique revolving sushi dining experience.We pay particular attention to the taste, sourcing, and preparation of all of our dishes. Nothing is more important to sushi than the rice and the vinegar. We evaluated over 100 varieties of rice before selecting the perfect one to mix with our secret vinegar recipe. Also, our philosophy of “muten” or “nothing added” is an ongoing promise that our food is prepared using natural ingredients with no additives or artificial preservatives.

In der vierten Folge der dritten Staffel "Moleküle auf dem Teller" geht es um Vitamine, die in ihrer Vielfältigkeit wohl durchaus etwas Magisches haben, was mich zum Titel inspiriert hat. In dieser Folge erfährst Du nun also, wie die einzelnen Vitamine funktionieren, wieso Vitamin D gar kein "echtes" Vitamin ist und wieso Vitamine so wichtig für Sportler*innen aller Disziplinen sind. Außerdem gibt es am Ende bereits einen kleinen Outlook: nächste Folge kannst Du dich auf Erklärungen zu Mineralstoffen freuen! Informationen zum Podcast Recherche und Skript: Anne Mayer, mit Unterstützung von ChatGPT 4o und o1 und Perplexity AI (Pro) Ton und Schnitt: ⁠⁠⁠Anne Mayer

Nach Ansicht von Filmemacher Andres Veiel schadet die Abstimmung der CDU mit der AfD nicht nur der Demokratie - die Forderungen zur Migrationspolitik sind auch gesetzeswidrig. CDU-Chef Merz gehe es um Aufmerksamkeit und er schüre Ängste. Veiel, Andres www.deutschlandfunkkultur.de, Fazit

Calli, Matze und Tobi freuen sich über immer mehr Hörer! Dann erfahren nämlich auch immer mehr, was wirklich los ist hinter den Kulissen der Bundesliga! Am Ende hält Lothar sowieso alle Strippen in der Hand, das ist jawohl klar!! Calli sagt, was bei Boniface Sache ist, CR7 ist ja eh einer seiner absoluten Lieblings-Spieler. Matze sorgt sich um die Nachfolge von Manuel Neuer bei den Bayern. Und Tobi weiß, warum Ralf Rangnick jetzt auf einmal ein Thema ist beim BVB. Es lebe, das ist auf jeden Fall Fakt, die heiligen Glaskugel von Lippstadt. "Echte Champions XXL" ist eine Produktion der Podcastbande. Neue Folgen immer donnerstags - überall, wo es Podcasts gibt.

How are artists navigating wealth transmission and estate planning in today's music industry? On this episode of the MUBUTV Music Business Insider Podcast entitled, 'Hold or Sell Your Music Rights The Surprising Truth Revealed' with Roland Kluger, we explore the motivations behind selling music catalogs, the role of Performance Rights Organizations, and how new platforms are changing the game. Discover how evolving copyright laws in the U.S. and Europe impact these decisions and the potential of emerging markets!

Telefon-Andacht vom 01.12.2024 von Jens Rohlfing

Electric vehicle sales may be currently on the wane however hybrid vehicle sales are enjoying boom conditions with 129,895 national sales in the first nine months, an increase of 87 percent on the same time last year. Petrol electric hybrid vehicles are clearly far more popular than plug-in hybrids which achieved 15,546 sales in the same period. Toyota which accounts for around 20 per cent of the total new vehicle market has had enormous success with its petrol/electric hybrid models which now represent around half its sales. Its RAV4 hybrid our top selling hybrid vehicle with 40,754 deliveries in the first nine months. Apart from the RAV4, Toyota now has five top selling petrol electric hybrids in Corolla, Camry, Kluger, Corolla Cross and Yaris Cross suggesting it has chosen the right sales strategy going forward. I'm David BerthonSee omnystudio.com/listener for privacy information.

Are you tired of being just another leader? Want to inspire your team, drive innovation, and build lasting relationships? The secret lies in a skill you may have overlooked: listening. Effective leadership often hinges on a surprising skill that can go unnoticed: listening. Raquel Ark shares that listening isn't just a soft skill; it's a powerful skill that can shape how you lead and influence. Imagine leading a team that's motivated, engaged, and full of ideas. Effective listening fosters trust, respect, and a positive work culture. It's can play an important role in increasing productivity and wellbeing for you and your team.  What if you could make better decisions, prevent explosive conflicts or manage tensions with more ease. Listening helps you connect with your team's needs, concerns, and aspirations, as well as your own. It's not just a skill; it's a superpower. Join Raquel as she explores the different types of power that listening can bring to leadership and everyday interactions, providing practical strategies to grow your listening superpower. "Listening is not just a soft skill. It's a power skill. It's a transformative force that shapes the way leaders like you, like me, connect, inspire, and lead." - Raquel Ark   Listening SUPERPOWER NOTES 00:10: Emphasizing the importance of listening as a transformative leadership skill. 01:28: The different types of power that listening can bring to leadership. 4:20: Discussion on the common undervaluation of listening in the business world compared to speaking, highlighting the impact of listening on effective leadership. 07:04: Presentation of research findings indicating a shift towards prestige-based leadership, which emphasizes listening and collaboration over autocratic dominance. 11:08: Conclusion on the significance of listening as a power skill that can transform organizations and drive sustained success, encouraging leaders to embrace listening in their practices.   Key Takeaways: "The true power of effective leadership lies in listening, which is often an overlooked skill or capacity that we have, or that's important to develop."- Raquel Ark   "When listening is brought into teams, those leaders are able to affect their teams in ways where they have more success and they feel better."  - Raquel Ark   "Listening is not just a tool. It's actually really cool. It's this high value currency that can transform organizations and really drive this sustained success."- Raquel Ark   "The leaders who listen are the ones who are going to lead us into the future."- Raquel Ark   Resources Mentioned:   Kluger, Avraham & Itzchakov, Guy. (2022). The Power of Listening at Work. Annual Review of Organizational Psychology and Organizational Behavior. 9. 10.1146/annurev-orgpsych-012420-091013 https://www.merriam-webster.com/dictionary/prestige https://action.deloitte.com/insight/2358/prestige-leadership-is-no-magic-trick-its-a-key-to-effective-teams   Recommended Episodes about Leadership in tech Navigating Digital Change by Leaning Into Tech and Expanding a Human Touch with Agathe Daae-Qvale Listening to the Pulse in Leadership: Nourishing Realistic Expectations and Intentionally Catalyzing Employee and Team Growth with Clint Calleja #Listening to Create #Customer and #Business Value with Teresa Torres Dynamic Reteaming: Mastering Team Change for Excellence Using Your Listening Muscle with Heidi Helfand Connect with Raquel Ark: https://listeningalchemy.com/  Mobile: + 491732340722 contact@listeningalchemy.com LinkedIn: Raquel Ark https://www.linkedin.com/in/raquel-ark-b2067613/ 

Meyer, Michael www.deutschlandfunk.de, @mediasres

Want to learn secrets about improving your business image, enhancing your communication in the boardroom or just want ways to engage and motivate team members? This episode Allison Kluger, whose pedigree goes from Good Morning America to teaching classes along side American idols like A-Rod and Tyra Banks, gives so many tips from her life time of helping people communicate to sell and enthrall. You will have frame works to get team mates on board and give you the confidence to drive in the direction in your life you know you want to.  Don't miss this awesome episode. More about Allison here https://www.allisonkluger.com/ 

Welcome to a new episode of The Film Stage Show! Brian Roan and Robyn Bahr are joined by Bryan Kluger to discuss Osgood Perkins' Longlegs. Enter our giveaways, get access to our private Slack channel, and support new episodes by becoming a Patreon contributor. All new Patreon supporters receive a free 4K UHD or Blu-ray upon joining. The Film Stage Show is supported by MUBI, a curated streaming service showcasing exceptional films from around the globe. Every day, MUBI premieres a new film. Whether it's a timeless classic, a cult favorite, or an acclaimed masterpiece — it's guaranteed to be either a movie you've been dying to see or one you've never heard of before and there will always be something new to discover. Try it for free for 30 days at mubi.com/filmstage.

Would you like to have more gravitas and charisma? Learn how to shift your mindset as well as your voice and body language to amplify your confidence, presence and power in everyday life. The listen to this episode..... Allison Kluger is an award-winning media expert who's well-known for her oversubscribed Personal Branding course at Stanford Business School. She has co-taught with the likes of Tyra Banks and Alex Rodriguez and will share her unique and cutting insights about leadership and establishing executive presence.  Todd Jason is an executive coach who's developed programs with some of the most sought after teachers in the world including Tony Robbins, Eckhart Tolle and Deepak Chopra.  He's the founder and lead facilitator of ASCEND - a community that assists thousands of people in regaining their personal freedom and heightening mental clarity.  Visit Todd's website and community here! Explore the ASCEND Community Lauren Weinstein is an executive coach known for her expertise in powerful communication and life transformation. She taught one of the most popular courses at Stanford Business School, has coached hundreds of executives from Fortune 500 companies, and her TEDTalk “Don't Believe Everything You Think” on unlocking your true potential now has over 3 million views. Visit Resonate Coaching and learn more about her coaching and programs!        

This week, Pat Cobe, senior menu editor at Restaurant Business, shared her take on Blank Street's summer matcha drinks and the escalating price of lobster rolls, while Bret Thorn, senior food & beverage editor of Nation's Restaurant News and Restaurant Hospitality, recounted his visit to Philadelphia to dine at Iron Hill Brewery & Restaurant and Zahav, chef Michael Solomonov's Israeli restaurant. The guest on this week's Menu Talk is Dan Kluger, chef-partner of Greywind in New York. Chef Kluger got his start working with Danny Meyer at Union Square Café, then moved on to Tabla, where he was mentored by the late chef, Floyd Cardoz. He talks about how his experience at Tabla really molded his palate and management style.

Yahrtzeit Yomi #1100!! ל סיון (Shabbos) Rav Shlomo Kluger רב שלמה ב״ר יהודה אהרן האלף לך שלמה (1786 - 1869) ---------------------------------------------------- Yahrtzeit Yomi for the final week of Sivan is dedicated לעילוי נשמת רב יעקב בן ר׳ אברהם ז״ל ת.נ.צ.ב.ה. ---------------------------------------------------- Share the Yahrtzeit Yomi link with your contacts!! https://chat.whatsapp.com/JimbwNtBaX31vmRDdnO3yk --------------------------------------------------- To dedicate or sponsor, please contact 917-841-5059. Sponsorships can be paid by Zelle to the same number. First come, first served. Monthly sponsorships are $540. Weekly sponsorships are $180. Daily sponsorships are as follows: Dedications (l'Zecher Nishmas, Zechus shidduch/refuah/yeshuah, etc.) are $50. Sponsorships (fliers, advertising, promotions, additional links, etc.) are $100. The cost to request and sponsor a specific Tzaddik (unlisted on the Yahrtzeit Yomi schedule) is $180. MAY THE ZECHUS OF ALL THE TZADDIKIM PROTECT US FROM ALL TZAROS, AND MAY HASHEM GRANT US, AND ALL OF KLAL YISROEL, A MONTH OF YESHUOS, NECHAMOS AND BESUROS TOVOS!!!

On pense souvent que la performance des équipes augmente quand les employés :

What's up, dudes? It's all about WWF Prime Time Wrestling Christmas 1986, battle royale style with Jeremy Phelps the Alamo City Santa,  CM Chuck from Just Another Friday Night, Joe from Now Watch This, Manny from Feliz Christmas, Merry Navidad, and CJ from Christmas Sessions! We talk Bobby the Brain and Gorilla! We dive into Hogan and Savage! We body slam Junkyard Dog and Harley Race! This episode has it all! Airing December 23, 1986, the matches begin with Jimmy Jack Funk taking on Blackjack Mulligan, who defeats Funk with little effort. Iron Mike Sharpe batted Special Delivery Jones—no, not S.D. Kluger from “Santa Claus is Comin' to Town! Jones takes Sharpe with an atomic drop. “What a Christmas present for S.D. Jones!”Meanwhile Bobby and Gorilla argue about presents. Means Gene spoke with Ricky “The Dragon” Steamboat and Jesse Ventura interviewed Andre the Giant. Harley Race defeated Pedro Morales and retained his crown. Subsequently, Dick The Rebel Slater stuns Steve Lombardi with a suplex. As well, Dino Bravo beat Corporal Kirchner. Junkyard Dog rammed Adrian Adonis into a turnbuckle to get out of a sleeper. Both men are tossed out of the ring, but JD gets back in before the count and wins! Finally, World Heavyweight Champion Hulk Hogan collided with the monstrous Hercules Hernandez. Hogan, seemingly in trouble, comes back off the ropes with a leg drop to pin and win!Stuffed gorilla gifts? Yep. Gold phone presents? Uh huh. Blackjack Mulligan's wagon of fertilizer?!?! What?!?? So grab your belt, get on the ropes, and backflip to this episode on Prime Time Wrestling Christmas 1986!Just Another Friday NightYouTube: @JAFNpodcastFB: @JAFNpodcastTwitter: @JAFNpodcastIG: @jafnpodcastNow Watch ThisFB: @nowwatchthispodTwitter: @nowwatchthispod IG: @now_watch_this_pod Feliz Christmas, Merry NavidadFB: @FCMNPodcastTwitter: @FCMNPodcastIG: @fcmnpodcastCheck us out on Facebook, Twitter, Instagram, Totally Rad Christmas Mall & Arcade, Teepublic.com, or TotallyRadChristmas.com! Later, dudes!

This episode of The Restaurant Growth Show features Robert Kluger, Chief Development Officer at Kura Sushi USA, discussing the brand's rapid expansion, technology-driven dining experience, and customer engagement strategies. Kura Sushi USA, known for its robot servers and conveyor belt sushi, has grown significantly since its U.S. launch in 2009. Kluger shares insights into the company's history, the role of technology in enhancing the dining experience, and strategic collaborations with popular franchises. Additionally, the discussion covers Kura Sushi's approach to customer satisfaction, loyalty programs, and the impact of technology on both front-of-house and back-of-house operations. Kluger also touches on Kura Sushi's recent foray into third-party delivery services and hints at future expansion plans. 00:02 The Rise of Kura Sushi USA: Innovation and Expansion 02:02 Behind the Scenes: Technology and Customer Experience at Kura Sushi 05:42 Exploring Kura Sushi's Unique Collaborations and Loyalty Programs 08:06 The Future of Dining: Automation, Expansion, and Customer Engagement 12:45 Kura Sushi's Strategy for Growth and Customer Satisfaction 15:54 Expanding Horizons: Kura Sushi's Plans for Delivery and International Growth To find a restaurant near you check out https://kurasushi.com/ and follow them on social at Kura Sushi USA Instagram: @kurasushi_usa Twitter: @kurasushi_usa Facebook: @kurasushiusa TikTok: @kurasushiusa

Bahn und GDL haben sich darauf geeinigt, stufenweise ein Wahlmodell für Schichtdienstler einzuführen. Er halte eine flexible Arbeitszeit und eine gute Bezahlung grundsätzlich für sinnvoll, sagt Marcel Fratzscher, Präsident des Deutschen Instituts für Wirtschaftsforschung (DIW). Denn gesunde, zufriedene Arbeitnehmer seien auch produktiver.

Thank you for joining me as I kick off part one of a special three-part series in celebration of Reppin's upcoming 100th episode milestone! ]Today, I am thrilled to welcome back the extraordinary Allison Kluger, who holds a special place in my heart as not only a past guest on Reppin but also as a dear friend with whom I share a history spanning over two decades. From her illustrious career as a television producer to her role as a cherished lecturer at Stanford Graduate School of Business, Allison brings a unique blend of experience and insight to the table. She's going to share more of her experiences, uncovering the secrets of success gleaned from working with industry giants like A-Rod and Tyra Banks. She not only back to empower you with the invaluable life lessons that garnered her so much deserving success. She also dishes on her experiences as a past guest on Reppin and offers behind-the-scenes stories about our shared journey that has spanned over twenty years. With her mantra of "Leading with Love," Allison guides us through the transformative power of empathy and authenticity in leadership, offering practical tips for personal branding, reputation management, and more. Whether you're a seasoned professional or just starting out, Allison's insights are sure to inspire and empower you on your own path to success. So grab your headphones and get ready for an enriching conversation filled with warmth, wisdom, and plenty of laughs! Don't forget to subscribe to Reppin for more uplifting content and join us on this journey of growth and discovery. Listening to this episode will provide you with actionable strategies and heartfelt anecdotes from a seasoned industry expert, helping you navigate your professional journey with confidence and authenticity. Whether you're looking to enhance your leadership skills, refine your personal brand, or simply gain inspiration from Allison's uplifting story, this conversation is packed with invaluable insights that will benefit you both personally and professionally. Listen now, you'll be inspired and you'll take the first step towards unlocking your full potential!

Essen und altes Wissen, so heißt das ungewöhnliche Kochbuch, das die Marktgemeinde Bad Hindelang herausgebracht hat. Darin gibt's nicht nur Rezepte, sondern auch Lebensgeschichten. Petra Kluger und Sabine Rödel stellen das Buch bei Bettina Ahne vor.

Welcome to your guide to the savory stories behind the chefs who are redefining dining, one dish at a time. In our latest episode of Chef AF, I had the pleasure of sitting down with none other than Dan Kluger, whose groundbreaking approach to seasonal and sustainable cooking has cemented his status as a vanguard of New York City's dining scene. Kluger, a James Beard Award-winning chef, shares his journey from learning under renowned chefs to opening his acclaimed restaurants, including the beloved Loring Place and the innovative Greywind.A Chef's Journey: From Learning to Leading in NYCDan Kluger's story is one of passion, creativity, and an unwavering commitment to showcasing local, seasonal ingredients. His culinary philosophy, deeply rooted in the rhythms of nature, transforms simple dishes into vibrant, flavor-packed creations. During the interview, Kluger recounts his early days in the industry, working under culinary titans like Jean-Georges Vongerichten and Tom Colicchio, and how these experiences shaped his approach to cooking and restaurant management.Greywind: A Culinary Gem in Hudson YardsIn our chat, Dan unveils the inspiration behind Greywind, his latest contribution to New York's vibrant dining scene. Nestled in Hudson Yards, Greywind marries the rustic beauty of the Hudson Valley with urban sophistication, a reflection of Dan's vision to create a dining experience that's as enriching as it is delicious. He also gives us a sneak peek into Spygold and The Bakery at Greywind, each a unique facet of his culinary empire, showcasing his commitment to innovation and excellence.GreywindWashington Squares: Reinventing Pizza with PurposeOur conversation took a delightful turn as Dan recounted the birth of Washington Squares. What started as a pivot during the pandemic became a beloved pizza destination, known for its soul-satisfying Grandma-style pies. Dan's story of adaptation and resilience resonates with anyone looking to make a positive impact, no matter the circumstances.The Chef's Counter: An Exclusive InvitationLooking ahead, Dan shares his excitement for the upcoming Chef's Counter at Greywind, an intimate setting where diners will be treated to a tasting menu that promises an unforgettable culinary journey. His passion for creating a dining experience that both challenges and delights is evident as he talks about this next adventure.Dan Kluger, Greywind | Photo Credit Evan SungDan Kluger: Crafting New York's Culinary NarrativeAs your host on Chef AF, I aim to bring you closer to the chefs shaping our food culture. Dan Kluger's episode is a compelling story of innovation, sustainability, and the magic of New York City's food scene. His dedication to celebrating local, seasonal ingredients not only defines his cuisine but also tells the larger story of what it means to dine in this great city.On Chef AF we continue to explore the culinary world through the eyes of those who are changing it one plate at a time. Dan Kluger's journey from the farm to the forefront of New York's culinary scene reminds us of food's power to connect, inspire, and transform.

“The very stone one kicks with one's boot will outlast Shakespeare.”― Virginia Woolf, To the LighthouseToday my guest is Kat Kluger. Kat & I play tennis together but know very little about one another off the court, until now. We all have a story, that is guaranteed, and just like any other guest, I am always blown away by the paths that life has lead them down. Kat is no exception. Growing up on the island of Kauai, life was both beautiful & a bit scarce & with no formal schooling until a later age. Now, life is much different for Kat in a way that she built for herself, still beautiful, still simple & 100% authentic.Check out Camp Couranthttps://campcourant.org/@theyrejusthumanswww.theyrejusthumans.com

Today we'll embark on a journey of innovation and environmental impact with Niklas Kluger, co-founder and COO of InPlanet. We'll learn how this GreenTech pioneer, with a rich background in environmental engineering and tropical agriculture, is revolutionizing carbon dioxide removal. From scaling urban farming globally to pioneering something I had never heard of called “Enhanced Rock Weathering” in Brazil, Niklas is at the forefront of combating climate change and regenerating tropical soils. Their rock powder is able to remove CO₂ while regenerating soil, two vitally important things for our sustainable future on this planet. So let's explore InPlanet's mission to create a carbon-neutral future, one gigaton at a time." ➡️ https://www.inplanet.earth/ ➡️ https://rosspalmer.com/niklas-kluger ➡️ Follow me on Instagram: @therosspalmer ➡️ Subscribe on YouTube: @therosspalmer

World renowned posek of the 19th century, prolific author and courageous leader, Rav Shlomo Kluger (1785-1869) achieved immortality in the Torah world through his nearly half century tenure as Magid and Av Beis Din in the prominent Galicia town of Brody. As political and economic changes swept through the Habsburg Empire over the course of the 19th century, traditional norms changed, technological advances brought new challenges and the hegemony of the traditional Kahal (Jewish communal autonomy) was irrevocably transformed. Rav Shlomo Kluger emerged as a charismatic and strong minded leader during this tumultuous time. Halachic queries arrived at his desk from all over Galicia and eventually from across Europe. He fought to maintain tradition and halachic norms despite attempts to modernize Jewish law. His literary legacy is almost unparalleled in Jewish history, and his many works are studied until this very day.   Cross River, a leading financial institution committed to supporting its communities, is proud to sponsor Jewish History Soundbites. As a trusted partner for individuals and businesses, Cross River understands the importance of preserving and celebrating our heritage. By sponsoring this podcast, they demonstrate their unwavering dedication to enriching the lives of the communities in which they serve. Visit Cross River at https://www.crossriver.com/   Subscribe to Jewish History Soundbites Podcast on: PodBean: https://jsoundbites.podbean.com/ or your favorite podcast platform Follow us on LinkedIn, Twitter or Instagram at @Jsoundbites For sponsorship opportunities about your favorite topics of Jewish history or feedback contact Yehuda at:  yehuda@yehudageberer.com  

Join us this week as we continue our series on being All In with Jesus as we welcome guest speaker Ernie Kluger talking over the importance of being all in for the training that God has for us as he teaches on Titus 2:11-15.

Playwright Garry Michael Kluger stopped by to sit in the Playwright's Spotlight to talk about all things playwriting and also touched on its from film and television. Having been a three-time semi-finalist, we discuss the process of and when to submit for the O'neill's and whether it's ever okay to pay to submit your work. We also touch on how playwrights one has never met can serve as a mentor, conversation being spontaneous while dialogue being scripted, and how one's characters dictate the verbiage as well as the difference between humor and comedy, learning how to say no, dusting off old and incomplete work, writers having the final word, creating layered characters, the misconceptions of playwriting, and the process of editing. We unpack so much more that I can't list them all. Garry offers so much insight that I walked away with so much information. I hope you find the same for you. Garry Michael Kluger has written 19 plays, 3 books, 2 TV pilots, several television series, and 12 documentaries and was a writing member of Theatre West; one of Los Angeles' most prestigious theatre companies. Three of his plays have been semi-finalists for the prestigious O'Neill Playwright's Conference. His play The Other Half, was a part of the 2014 Pittsburgh New Works Festival and WestFest at Theatre West in Los Angeles, and Top Ten at the Sterts Playwrights Festival in London. The Homecoming, was a finalist in the Warner International Playwrights Festival, the West Hollywood Gay and Lesbian Play Reading Festival, and winner of the Chaos Theory Play Festival in 2011. In 2010 his play Brotherhood won “The Audience Favorite” as a part of the Hollywood Fringe Festival at the Tre Stage. In 2009, he was honored to receive the prestigious Red Carpet Award from Women In Theatre for his contributions, as a playwright, to Los Angeles theatre.To view the video format of this episode, visit -https://youtu.be/CFzEgdpHhesLinks to sites and resources mentioned in this episode - The O'neill -https://www.theoneill.org/npcThe Pulitzer -https://www.pulitzer.org/Theatre West -https://theatrewest.orgTickets for Walking in Space -www.wis2023.com or - https://ci.ovationtix.com/35048/production/1171437Contact information and socials for Garry Michael Kluger -Website -www.iktproductions.comFacebook - https://www.facebook.com/garry.klugerTwitter - @baroyIG - @baroyWebsites and socials for James Elden, Punk Monkey Productions and Playwright's SpotlightPunk Monkey Productions - www.punkmonkeyproductions.comPLAY Noir -www.playnoir.comPLAY Noir Anthology –www.punkmonkeyproductions.com/contact.htmlJames Elden -Twitter - @jameseldensauerIG - @alakardrakeFB - fb.com/jameseldensauerPunk Monkey Productions and PLAY Noir - Twitter - @punkmonkeyprods                  - @playnoirla IG - @punkmonkeyprods       - @playnoir_la FB - fb.com/playnoir        - fb.com/punkmonkeyproductionsPlaywright's Spotlight -Twitter - @wrightlightpod IG - @playwrights_spotlightPlaywriting services through Los Angeles Collegiate Playwrights Festivalwww.losangelescollegiateplaywrightsfestival.com/services.htmlSupport the show

Please join us Right Now, August 28, 2023 at 11:00AM PST as Actor Patrick Faucette and Playwright, Author, Actor Garry Michael Kluger host Ron Brewington on "The Actor's Choice."

Eva-Maria Seidl blickt als studierte Kulturwirtin auf über zwölf Jahre Erfahrung in verschiedenen Positionen der Foodbranche zurück. Sie kümmert sich um die strategische Weiterentwicklung des Frauennetzwerk FOODSERVICE. Aufgrund langjähriger Führungspositionen ist Eva-Maria bestens vernetzt und bringt starke internationale Erfahrung in den Vorstand und hat eine klare Vision für Frauen in der Foodbranche: „Wir erleben gerade einen Wandel – nach der Generation der Einzelkämpferinnen sind wir die erste Generation, in der Frauen gemeinsam „Change“ und „Impact“ im Business-Bereich aktiv mitgestalten. Frauen müssen sich helfen, fördern und Türen öffnen.“

Hello this is Overdrive a program that looks at the purpose of and the passion for trains, planes and automobiles I'm David Brown The times each story appears in the program are noted (mm:ss) Feature I had the privilege of attending the Unlimited 5.0 Launch — The latest solar racer from Western Sydney University's Solar Racing Team. The level of professionalism in this group of young adults was outstanding. We Road test a couple of Toyota's – the Corolla Cross and the Kluger large SUV And Dean, Fred and I chat about some car shows we have been to in the last week. Motoring Minutes For more information Driven Media Social media – Face Book and Instagram search for “Cars transport culture” Podcasts iTunes: Cars Transport Culture Spotify: Cars Transport Culture Facebook Cars Transport Culture Instagram Cars Transport Culture Our YouTube site Cars Transport Culture Originally broadcast on 12 August 2023

This is a Meditation from Rav Avraham Tzvi Kluger Shlita. In this series, Yakov offers user friendly techniques for grounding, getting present, and increasing our capacity for meaningful connections and experiences. People often develop patterns of how they experience themselves and the world around them. While these patterns can be helpful, they can also become unknowingly narrow and constricting. Attached is about expanding the range of ways that we engage our lives. Opening our minds, emotions, bodies, and souls to experience the fullness of our multidimensional selves and endlessly varied world. Attached is rooted and focused on Jewish tradition and wisdom along with psychology, philosophy, and relevant wisdom wherever it may be found. Rabbi Yakov Danishefsky LCSW CSAT is the founder of Mind Body Therapy, a private group practice in Chicago. He is a popular speaker and teacher for congregations, organizations, and schools. He is the author of a new book, Attached: Connecting to Our Creator, a Jewish Psychological Approach. Please contact us with questions and comments, or to be added to our WhatsApp lists here or by email at Yakov.attached@gmail.com Our content can also be found on Spotify and YouTube

"Die KI wird gerade zu einem mächtigen Ermöglicher für technischen Fortschritt", sagt der Informatiker Björn Ommer. Er hat den Text-zu-Bild-Generator "Stable Diffusion" entwickelt, bei dem die KI aus eingegebenen Befehlen Bilder erschafft. Der Mensch habe immer schon Technologie gebaut, um seine Fähigkeiten zu verbessern. Mit der Künstlichen Intelligenz könne man selbst Probleme wie den Klimawandel angehen. Dafür brauche es aber weltweit einen "Diskurs darüber, welche Werte wir überhaupt hochhalten". KI ein Brennglas für lange bekannte Probleme "Ich denke, die KI ist ein Brennglas für Probleme, die schon vorher dagewesen sind", meint der Professor des Lehrstuhls "Künstliche Intelligenz und Kulturanalytik" der LMU München. Es brauche für einen klugen Umgang mit KI vor allem Bildung in allen Alters- und sozialen Schichten. Erst der Anfang Dabei sei der Markt heute noch stark von Prototypen bestimmt. "Das ist erst der Anfang von etwas viel, viel Größerem", meint Ommer. Bald schon könne der Mensch dank KI viel produktiver mit dem Computer arbeiten. Da sei es "nicht zu spät und selten zu früh", über funktionierende Regulierung nachdenken. "Wir schaffen das auch bei der KI, wenn wir das wollen!" Teil des Festivals der Zukunft Beim Festival der Zukunft im Deutschen Museum in München (6.-9.7.) spricht Björn Ommer in einem Panel darüber, wie man mit KI Positives für die Gesellschaft bewirken kann, in seinem eigenen Vortrag führt er das Thema weiter aus.

In this week's episode of the Neurophilia Podcast, we discussed the relationship between Neurology and Palliative Medicine, the need for empathy and vulnerability in patient conversations, the emerging field of Neuropalliative Medicine, how to celebrate the small victories in medicine, and even Dua Lipa! In this episode, we are joined by Dr. Kathleen Neuendorf and Dr. Renato Samala.Dr. Kathleen Neuendorf, MD has been a palliative medicine physician, working primarily as a consultant in the hospital, since 2010. She was drawn to the field because it brought an honesty and clarity that people seemed to need but weren't always getting. Dr. Neuendorf is known both locally and nationally for her work in relationship-centered communication and leadership. Outside of work, she is a proud mom of 3, enjoys spending time with her husband and taking walks in the Metroparks.Dr. Renato V. Samala, MD is a staff physician in the Department of Palliative and Supportive Care at the Taussig Cancer Center, and an Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine. After graduating from the University of the Philippines College of Medicine, he completed a residency in internal medicine at UPMC McKeesport, and fellowships in Geriatrics and Hospice and Palliative Medicine at Cleveland Clinic. Dr. Samala is a fellow of the American College of Physicians and the American Academy of Hospice and Palliative Medicine. He has written numerous articles published in peer-reviewed journals and textbooks, and has presented at local, national and international conferences.References:Boersma, I., Miyasaki, J., Kutner, J., & Kluger, B. (2014). Palliative care and neurology: Time for a paradigm shift. Neurology, 83(6), 561–567. https://doi.org/10.1212/wnl.0000000000000674 Brizzi, K., & Creutzfeldt, C. (2018). Neuropalliative care: A practical guide for the neurologist. Seminars in Neurology, 38(05), 569–575. https://doi.org/10.1055/s-0038-1668074 Creutzfeldt, C. J., Robinson, M. T., & Holloway, R. G. (2016). Neurologists as primary palliative care providers. Neurology: Clinical Practice, 6(1), 40–48. https://doi.org/10.1212/cpj.0000000000000213 Silveira, M. R., & Forte, D. N. (2022). Palliative care and neurology: A path to neuropalliativism. Arquivos de Neuro-Psiquiatria, 80(5 suppl 1), 328–335. https://doi.org/10.1590/0004-282x-anp-2022-s119 Taylor, L. P., Besbris, J. M., Graf, W. D., Rubin, M. A., Cruz-Flores, S., & Epstein, L. G. (2022). Clinical guidance in neuropalliative care. Neurology, 98(10), 409–416. https://doi.org/10.1212/wnl.0000000000200063 Zehm, A., Hazeltine, A. M., Greer, J. A., Traeger, L., Nelson-Lowe, M., Brizzi, K., & Jacobsen, J. (2019). Neurology clinicians' views on Palliative Care Communication. Neurology: Clinical Practice, 10(6), 527–534. https://doi.org/10.1212/cpj.0000000000000794 Support the show

They say nice guys finish last and there is some truth to that. Life isn't easy and no matter who you are or where you live, we all have to deal with difficult situations and people. This is certainly true in a wonderful but often times volatile industry like entertainment. But my guest, Allison Kluger has been able to do just that. Throughout her time in media, she has been able to navigate through a maze of chaos and sometimes explosive situations with class and integrity. She's had a very successful career in television with credits that include Good Morning America, she was one of the original hires and worked alongside Barbara Walters on The View, and then with Al Gore on his start up, Current TV. Now, she she's a lecturer at Standford University and has her own consulting firm. Allison shares how she's been able to succeed without compromising her integrity, character and goodness. She's an award winning media expert that major power players like Alex Rodriguez and Tyra Banks call upon and have on their team to consult them on their business ventures. This is a story about how create new opportunities for yourself, how to be resolute in your character, and how empathy and kindness are incredible strengths. So grab a pen and get ready to take some notes on how to succeed with compassion and how to navigate the high stakes game of life. Learn more about your ad choices. Visit megaphone.fm/adchoices

What does it mean to truly listen in a way that has enormous impact, also in the business world?  When we commit to truly listening to someone, we open doors for quality connections that can lead to transformation and relationship satisfaction. It's through listening that we can build bridges of understanding, empathy, and trust that allow us to connect with people on a deeper level. This, in turn, positively impacts organizational outcomes. In today's episode, we have a special guest, my good friend and mentor,  Dr. Avi Kluger, who is a renowned expert in the field of listening and a great listener.  Dr. Avi Kluger is a professor of organizational behavior at the Hebrew University of Jerusalem and his area of research focuses on the dangers of feedback and the benefits of listening in relationships and at work.  Avi has published numerous studies on the topic of listening in leading publications, including a meta-analysis on the power of listening at work. He was the Director of the Executive MBA program of the School (2010-2014). In his capacity as a director, he put strong emphasis on helping executives develop soft skills (e.g., negotiation, listening, self-presentation) in addition to developing an integrative view of the business. In this episode, Avi shares his insights on the definition of listening, which may surprise you. And that with listening, it may be hard, but the rewards of a deep and meaningful connection are more than worth it. If you commit to listen, you will find your relationships transform and flourish. Because then you open yourself up to the vulnerability of someone else's thoughts and emotions, and allow them to touch your heart. "Listening appears to create first and foremost good connections, good relationships, trust, and relationship satisfaction." - Avi Kluger Listening SUPERPOWER Notes: 01:25 - One experience when he felt the power of listening truly working 04:32 - How listening creates quality connections that reduces depression, anxiety and fosters vigor for life 10:20 - Discussing a question included in a listening research paper: Can we get rid of the adjective? 12:30 - Defining listening: Devotion to being with the other. 19:18 - Getting a little deeper into what it means to decide to devote yourself into listening 22:20 - What makes listening so hard: Because you have to completely let go. 26:16 - How listening lays the foundation of good connection with the ripple effect of relationship satisfaction 29:53 - Creating a challenge through listening even when things are already going smoothly 31:05 - Avi imparting some gold of wisdom: You decide to listen. It's gonna be hard. If you commit yourself, you may find that your prison walls are moving away from you and you have much more freedom in your life. Notes/Mentions: Kluger, A. N., & Itzchakov, G. (2022). The power of listening at work. Annual Review of Organizational Psychology and Organizational Behavior, 9, 121-146. https://doi.org/10.1146/annurev-orgpsych-012420-091013 Jane Dutton: https://michiganross.umich.edu/faculty-research/faculty/jane-dutton Guy Itzchakov: https://listeningalchemy.com/listen-in/listening-research-and-its-power-with-associate-professor-guy-itzchakov/  Key Takeaways: "Those fleeting moments of high quality connection, something in us changes for the better and as a result of it, it's like a deposit in our mental wellbeing bank. It reminds us that we are connected, reduces our depression, anxieties, and provides us with vigor for life, combined with sometimes new understanding of ourselves, the world, or both." - Avi Kluger "If you decide to devote yourself, it's a continuous decision, because this devotion could be for two minutes. It may disappear, you may bring it back and the devotion could be created by the listener, but it could also be created by the speaker." - Avi Kluger "Every time you go into this space of true connection with another human being, you're being transformed." - Avi Kluger "Many people are so lonely, entrenched in their own political camp. They cannot see the humanity of people from the other side, let alone listen to them." - Avi Kluger "We are sticking to what we know and to the worldview that we have. And this prison is serving us well. But the question is, is it well enough?" - Avi Kluger "While listening may take away time from work, it actually saves in the long term…a lot of time and creates better outcomes." - Avi Kluger "Once good relationships are created, more knowledge transfers in the organization, more positive attitudes are formed, like job satisfaction, motivation, and hence, and we see evidence of better performance, including objective measures of performance." - Avi Kluger Connect with Avi Kluger: Website: https://www.avi-kluger.com/  LinkedIn: https://www.linkedin.com/in/avikluger/  Connect with Raquel Ark: www.listeningalchemy.com Mobile: + 491732340722 contact@listeningalchemy.com   LinkedIn Podcast email: listeningsuperpower@gmail.com   

Guy Itzchakov knows how to listen. He's an associate professor in the Department of Human Services at the University of Haifa. He studies the markers of high-quality listening. But it's not that he tries to figure out who listens well and who doesn't. Instead, he's focused on how receiving high-quality listening affects us as speakers. He finds, for example, that when someone really, deeply listens to what we have to say, it provides us with a safe opportunity to explore where we really stand, realizing that the world is more nuanced than our simple opinions make them out to be. In our conversation, Guy shares the hallmarks of quality listening and what impact they have on speakers.Things that come up in this episode:Psychologist Carl Rogers and his pioneering work on person-centric therapy and empathic listening. Sources for the intro included: Boettcher, Hofmann, and Wu (Noba Textbook); Owen (2022); Rogers and Roethlisberger (1952)The markers of good listening: attention, comprehension, and positive intention (see Kluger & Itzchakov, 2022)Being listened to can lead people to openly acknowledge their ambivalence (Itzchakov et al., 2017) while becoming more clear in their views (Itzchakov et al., 2018).Speakers who experienced high-quality listening became less prejudiced in their views of other groups (Itzchakov et al., 2020)For a transcript of this episode, visit this episode's page at: http://opinionsciencepodcast.com/episodes/Learn more about Opinion Science at http://opinionsciencepodcast.com/ and follow @OpinionSciPod on Twitter.

In Berlin wird eine schwarz-rote Koalition wahrscheinlicher. Der SPD-Landesvorstand hat sich für Koalitionsverhandlungen mit der CDU ausgesprochen. Ob das eine kluge Entscheidung ist, kommentiert Markus Feldenkirchen vom "Spiegel". Außerdem hat Tom Böttcher Brandenburgs Ministerpräsidenten Dietmar Woidke gefragt, welche Perspektiven die Lausitz nach dem Ende der Braunkohle hat. Und es geht um zivile Seenotrettungsschiffe auf dem Mittelmeer, denen Einschränkungen drohen.

Rav Kluger on The Proper Perspective on Parnassah by Rabbi Avi Zakutinsky

Mark practices exclusively in the area of labor and employment law on behalf of employers. For ten years, before founding Kluger Healey, LLC, he was Chairman of the Labor and Employment Department of one of New Jersey's oldest law firms. Mark is a frequent speaker and writer on sexual harassment and discrimination avoidance, workplace diversity, performance management, union avoidance, and a myriad of other employment-related subjects and regularly conducts training sessions for employers on these critical topics. In addition, Mark has extensive experience in counseling employers on issues involving discipline and discharge, reductions in force, mergers and acquisitions, compliance with wage and hour, disability, COBRA, and family and medical leave laws. He regularly drafts all forms of employment policies and handbooks, severance agreements, employment contracts, non-competition and confidentiality agreements, and affirmative action plans. Mark also represents employers in collective bargaining, grievance arbitration, NLRB proceedings, and picket line issues. Mark graduated from Vassar College in 1984 and Cornell University Law School in 1987. He was an Adjunct Professor at Seton Hall Law School from 1991-1996 and served as a member and President of the Board of Education in North Caldwell, New Jersey from 2002-2008.

Rav Kluger's Machshava on Shabbos Part 2- Shabbos Clothing & Tosefes Shabbos by Rabbi Avi Zakutinsky

What's up, dudes? While I'm preparing for the Raddies--there are a lot of limos to rent, flights to book, seating to arrange, etc.--I decided to release a couple of minisodes! First comes some mail from S.D. Kluger's mailbag for Rad Santa. After that, you voted, and your votes were heard! With the help of a few of my Christmas podcast friends and colleagues, I compiled THE DEFINITIVE '80s recast of the the beloved holiday classic "Elf", starring Will Farrell. If you don't agree with this list, well you're wrong. Just kidding. There were a ton of great ideas, and it was super hard to choose! So sit back and dig into this short episode! Special thanks to CJ Belanger, Vinnie Brezinsky, Todd Killian, Chris Sisley, Manny Torres, Craig Kringle, Art Kilmer, Mike Westfall, and Anthony Caruso!